Trudeau Institute is a biomedical research enterprise dedicated to infectious disease research and development, where we confront some of the world’s most urgent public health crises. As a hub for streamlined rapid-response partnerships, we are battling drug-resistant TB, and joining forces in vaccine R&D on emerging pandemic threats, and accelerating new routes to eradicating the planet’s most deadly pathogens. Our renowned team is deploying its expertise in immunology and viral and bacterial pathogenesis to develop new medicines that boost immunity and defend against infectious threats — safeguarding our planet from deadly outbreaks and new pandemics.

This is **TRUDEAU 3.0**, and we are intrepid in our resolve to safeguard human health in New York State, across the United States, and around the globe.

**OUR HISTORY: SEEKING A CURE**

Our institute was founded in 1884 as a tuberculosis sanatorium, where patients could “cure” in the pristine mountain air under the care of founder **E.L. Trudeau**. A physician and TB survivor himself, Dr. Trudeau also undertook foundational tuberculosis research at his Saranac Lake Laboratory, the first lab built in the United States for the research of tuberculosis. In the 1960s, his grandson, **Frank Trudeau**, also a physician, transformed the sanatorium into a world-class immunology research center. This new “Trudeau Institute” grew into a flourishing research facility, and it was here that scientists achieved breakthroughs in understanding how the immune system becomes activated and suppressed — a foundation that continues to transform medical innovations today.

**OUR MISSION CONTINUES. AND EVOLVES.**

Trudeau Institute was founded on a bold premise: that rigorous science, executed from the heart of the Adirondack Mountains, could result in meaningful advances in public health. We’ve honed that signature expertise in immunity against pathogens and today, under the leadership of our new president, **Dr. Atsuo Kuki**, we’re putting these capabilities to work within larger-scale medical research ventures, to combat 21st century global health crises.

We are transforming the infectious diseases R&D ecosystem, so it can more nimbly respond to emerging viruses, insect-borne pandemics, and drug-resistant infections in the young and the elderly, in crowded cities and our nation’s hospitals, and wherever our military is deployed.
INFECTIOUS DISEASES. THE GREATEST THREAT TO CIVILIZATION?

In his April 2015 TED Talk, “The next outbreak? We’re not ready,” Bill Gates homes in on the threat: “When I was a kid, the disaster we worried about most was a nuclear war ... If anything kills over 10 million people in the next few decades, it's most likely to be a highly infectious virus ... Not missiles, but microbes.”

Tuberculosis killed 1.8 million people in 2015, and is the #1 infectious disease killer on the planet. The Zika virus began its rapid spread across Latin America and into the United States, permanently inflicting damage on newborns. And two million Americans contracted antibiotic resistant bacterial infections, including new strains of drug-resistant superbugs, most often among older patients in hospitals, or among wounded soldiers, or among those with suppressed immune systems, but also among the young and healthy.

CONFRONTING THE BIGGEST GLOBAL THREATS. FROM THE ADIRONDACKS.

To combat these crises head-on, we have established the medically-focused and highly-adaptable Trudeau Research Network (TRN), an alliance of New York State, national, and global biomedical research institutions and private enterprises, with Trudeau Institute as its nerve center. Our current staff on-site is 50 and growing. This strategy puts our current strengths to work, while joining forces with other key institutions, to best respond to urgent state and federal calls for innovations in combatting infectious disease. In doing so, we are transforming our operating and revenue models, to best leverage this distributed expertise, and so we can deliver life-changing science from the beauty and grandeur of the Adirondack Park.

Continuing the scientific legacy we have inherited, our research focuses on several key areas, all related to the human immune system: Tuberculosis, Influenza, and other Pulmonary Infections; Emerging insect-borne viral threats; Antibiotic-Resistant Bacteria; the Aging Immune System (targeting diseases like shingles, which attack the elderly and immunocompromised) and Immunosenescence (the gradual deterioration of the immune system).

TRN is a dynamic network that welcomes visionary partners. United in this pursuit, we will seamlessly transform medicine together.

We invite you to join us in advancing this endeavor, as we deploy our capabilities to catalyze breakthrough medical advances for patients both here and abroad, while preserving, honoring, and extending the Trudeau Legacy.

Dr. Atsuo Kuki, President and Director • akuki@trudeauinstitute.org • 518.354.9007
Suzanne Chapman, Strategic Administrative Coordinator • schapman@trudeauinstitute.org • 518.891.3080

TRUDEAUINSTITUTE.ORG

View from the patio of Trudeau Institute by David Martin